Rivastigmine

Parkinson Disease, Parkinson Disease, Dementia + 2 more
Treatment
8 FDA approvals
14 Active Studies for Rivastigmine

What is Rivastigmine

RivastigmineThe Generic name of this drug
Treatment SummaryRivastigmine is a medication used to treat mild to moderate Alzheimer's dementia. It works by increasing the amount of a chemical messenger in the brain which helps to improve memory and thinking skills. Rivastigmine is a type of drug known as a cholinesterase inhibitor, which works by blocking the breakdown of two important chemicals in the brain.
Rivastigmine Tartrateis the brand name
image of different drug pills on a surface
Rivastigmine Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Rivastigmine Tartrate
Rivastigmine
2000
128

Approved as Treatment by the FDA

Rivastigmine, also known as Rivastigmine Tartrate, is approved by the FDA for 8 uses including mild Dementia due to Parkinson's disease and Alzheimer Disease .
mild Dementia due to Parkinson's disease
Helps manage mild Dementia due to Parkinson's disease
Alzheimer Disease
Helps manage mild Dementia of the Alzheimer's Type
mild Dementia of the Alzheimer's Type
Helps manage mild Dementia of the Alzheimer's Type
moderate Alzheimer's Type Dementia
Helps manage moderate Alzheimer's Type Dementia
moderate Dementia due to Parkinson's disease
Helps manage moderate Dementia due to Parkinson's disease
Alzheimer's Disease
Helps manage moderate Alzheimer's Type Dementia
Parkinson Disease
Helps manage moderate Dementia due to Parkinson's disease
Parkinson Disease
Helps manage mild Dementia due to Parkinson's disease

Effectiveness

How Rivastigmine Affects PatientsRivastigmine works by increasing the levels of a brain chemical called acetylcholine. Acetylcholine plays an important role in memory and thinking, and is known to be in low levels in people with Alzheimer's disease. Rivastigmine is thought to do this by blocking the enzyme (cholinesterase) that breaks down acetylcholine. However, as the disease progresses and fewer neurons are working, the effectiveness of rivastigmine may lessen.
How Rivastigmine works in the bodyRivastigmine works by blocking the enzymes that break down acetylcholine, a chemical in the brain that helps send messages between nerve cells. This means that the amount of acetylcholine in the brain increases, which can help improve thinking and memory. Rivastigmine is more effective in the brain than other parts of the body, so it can help with cognitive issues without causing too many side effects.

When to interrupt dosage

The proposed dosage of Rivastigmine is contingent upon the diagnosed state, such as Parkinson Disease, Parkinson Disease and Alzheimer's Disease. The dosage amount vacillates as per the technique of administration (e.g. Patch, extended release - Transdermal or Capsule - Oral) delineated in the table below.
Condition
Dosage
Administration
Dementia
1.5 mg, , 3.0 mg, 4.5 mg, 6.0 mg, 0.46 mg/hour, 1.33 mg/hour, 0.95 mg/hour, 0.46 mg/[USP'U], 4.6 mg, 9.5 mg, 13.3 mg, 0.95 mg/[USP'U], 2.0 mg/mL, 9.0 mg/cm2, 1.8 mg/cm2
, Oral, Capsule, Capsule - Oral, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Solution, Patch - Transdermal, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Patch, Solution - Oral
Parkinson Disease
1.5 mg, , 3.0 mg, 4.5 mg, 6.0 mg, 0.46 mg/hour, 1.33 mg/hour, 0.95 mg/hour, 0.46 mg/[USP'U], 4.6 mg, 9.5 mg, 13.3 mg, 0.95 mg/[USP'U], 2.0 mg/mL, 9.0 mg/cm2, 1.8 mg/cm2
, Oral, Capsule, Capsule - Oral, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Solution, Patch - Transdermal, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Patch, Solution - Oral
Parkinson Disease
1.5 mg, , 3.0 mg, 4.5 mg, 6.0 mg, 0.46 mg/hour, 1.33 mg/hour, 0.95 mg/hour, 0.46 mg/[USP'U], 4.6 mg, 9.5 mg, 13.3 mg, 0.95 mg/[USP'U], 2.0 mg/mL, 9.0 mg/cm2, 1.8 mg/cm2
, Oral, Capsule, Capsule - Oral, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Solution, Patch - Transdermal, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Patch, Solution - Oral
Alzheimer's Disease
1.5 mg, , 3.0 mg, 4.5 mg, 6.0 mg, 0.46 mg/hour, 1.33 mg/hour, 0.95 mg/hour, 0.46 mg/[USP'U], 4.6 mg, 9.5 mg, 13.3 mg, 0.95 mg/[USP'U], 2.0 mg/mL, 9.0 mg/cm2, 1.8 mg/cm2
, Oral, Capsule, Capsule - Oral, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Solution, Patch - Transdermal, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Patch, Solution - Oral
Alzheimer Disease
1.5 mg, , 3.0 mg, 4.5 mg, 6.0 mg, 0.46 mg/hour, 1.33 mg/hour, 0.95 mg/hour, 0.46 mg/[USP'U], 4.6 mg, 9.5 mg, 13.3 mg, 0.95 mg/[USP'U], 2.0 mg/mL, 9.0 mg/cm2, 1.8 mg/cm2
, Oral, Capsule, Capsule - Oral, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Solution, Patch - Transdermal, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Patch, Solution - Oral

Warnings

Rivastigmine Contraindications
Condition
Risk Level
Notes
Anniversary Reaction
Do Not Combine
There are 20 known major drug interactions with Rivastigmine.
Common Rivastigmine Drug Interactions
Drug Name
Risk Level
Description
Metoclopramide
Major
The risk or severity of adverse effects can be increased when Rivastigmine is combined with Metoclopramide.
Acetylcholine
Minor
The risk or severity of adverse effects can be increased when Rivastigmine is combined with Acetylcholine.
Agmatine
Minor
The therapeutic efficacy of Agmatine can be decreased when used in combination with Rivastigmine.
Alcuronium
Minor
The therapeutic efficacy of Alcuronium can be decreased when used in combination with Rivastigmine.
Amantadine
Minor
The therapeutic efficacy of Amantadine can be decreased when used in combination with Rivastigmine.
image of a doctor in a lab doing drug, clinical research

Rivastigmine Novel Uses: Which Conditions Have a Clinical Trial Featuring Rivastigmine?

17 active clinical trials are currently investigating the potential of Rivastigmine to ameliorate Dementia, Alzheimer's Disease and mild forms of Alzheimer's Type Dementia.
Condition
Clinical Trials
Trial Phases
Parkinson Disease
0 Actively Recruiting
Alzheimer's Disease
3 Actively Recruiting
Phase 3, Phase 2
Parkinson Disease
0 Actively Recruiting
Dementia
11 Actively Recruiting
Phase 4, Phase 1, Not Applicable, Phase 2
Alzheimer Disease
0 Actively Recruiting

Rivastigmine Reviews: What are patients saying about Rivastigmine?

5Patient Review
10/14/2013
Rivastigmine for Dementia associated with Parkinson's Disease
My mother took this medicine for only 3 days and had very bad diahrea, dehydrated, weakness, tired. She ended up in the hospital for 2 days!
5Patient Review
6/14/2017
Rivastigmine for Dementia associated with Parkinson's Disease
I experienced some really bizarre dreams while using this treatment, and unfortunately it didn't actually help with my problem. It felt like a total ripoff.
4.7Patient Review
8/9/2008
Rivastigmine for Dementia associated with Parkinson's Disease
3.7Patient Review
5/19/2015
Rivastigmine for Mild to Moderate Alzheimer's Type Dementia
I may not have gotten my lost memories back, but the rate of memory loss has decreased since I started this treatment. Additionally, it seems to take less time for me to recall memories now.
2.3Patient Review
5/22/2013
Rivastigmine for Dementia associated with Parkinson's Disease
I accidentally gave my dad 12mg instead of 6mg a day. I didn't realize it until after a month later when I changed his dosage back to 6mg. Now he's complaining of headaches, sleepiness, and not being able to walk very well. His doctor won't return my phone calls until after the weekend. Is this normal response to the change in medication?
1.7Patient Review
9/30/2015
Rivastigmine for Mild to Moderate Alzheimer's Type Dementia
I've been taking this for a year now, and it's helped my memory some. I tried to quit taking it a few months ago but noticed my memory getting worse, so I started back up again.
1.3Patient Review
9/13/2010
Rivastigmine for Mild to Moderate Alzheimer's Type Dementia
1Patient Review
7/3/2018
Rivastigmine for Dementia associated with Parkinson's Disease
Unfortunately, this medication has never agreed with me. Every time I have taken it, I have experienced intense nausea and vomiting, dizziness, an accelerated heartbeat, and paranoia.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about rivastigmine

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Does rivastigmine slow down dementia?

"Although transdermal rivastigmine may improve cognitive function or slow cognitive decline, it does not cure Alzheimer's disease or dementia in people with Parkinson's disease."

Answered by AI

What class of drug is rivastigmine?

"Rivastigmine is a type of medication that is designed to help improve mental function by increasing the levels of a natural substance in the brain."

Answered by AI

What does rivastigmine do to the brain?

"Rivastigmine is an acetylcholinesterase inhibitor that increases levels of the brain chemical acetylcholine, allowing for better communication between nerve cells. This can improve the symptoms of dementia. Rivastigmine can be taken as capsules or liquid orally, or applied as a patch to the skin."

Answered by AI

Does rivastigmine make you sleepy?

"This medicine can cause some people to become dizzy, drowsy, or less alert than they are normally. If this happens to you, do not drive, use machines, or do anything else that could be dangerous until you know how this medicine affects you."

Answered by AI

Clinical Trials for Rivastigmine

Image of Rush University Medical Center in Chicago, United States.

Caregiver Support for Dementia

18+
All Sexes
Chicago, IL
Lewy Body Dementia (LBD) is the second most common form of degenerative dementia, affecting at least 2.4 million US adults, and the overwhelming majority of persons living with LBD (PLBD) are cared for by family caregivers. LBD caregiver strain: 1) exceeds that of non-LBD dementia caregivers; 2) worsens caregiver physical and mental health; and 3) increases the risk of PLBD hospitalization and institutionalization. LBD progression is complicated by combined motor, cognitive, and neuropsychiatric decline, and is punctuated by falls, infections, dehydration, and neuropsychiatric symptoms leading to acute healthcare utilization. Although family caregivers are uniquely positioned to identify and manage these challenges, which may avert emergency department visits and reduce morbidity, many caregivers lack the knowledge, skills, confidence, resources, and support to do so. The study team aims to 1) quantify the impact of PERSEVERE on caregiver knowledge, attitudes, mastery, and strain; 2) identify the intervention and mentor factors determining implementation fidelity; and 3) test the effects of PERSEVERE on PLBD quality of life and healthcare utilization. This will be accomplished in an NIH Behavioral Model Stage II national, randomized, attention-controlled, 12-week trial of PERSEVERE in 502 LBD caregivers in partnership with the Lewy Body Dementia Association, Parkinson's Foundation, and LBD Caregiver Advisors. The study team will match intervention arm caregivers with a trained peer mentor who will coach them through a modular, theory-based curriculum on LBD knowledge and social support. Attention-control participants will receive weekly, curated links to educational materials. The study team will identify immediate and delayed intervention effects, including mediators of strain at 12 weeks, and caregiver strain and PLBD outcomes at nine months. Implementation fidelity and PLBD healthcare utilization will be tracked biweekly. Qualitative methods will explore the intervention- and mentor-specific factors predicting fidelity, mentee outcomes, and retention. Remote recruitment, mentoring, and community engagement strategies will maximize accessibility and inclusion of underrepresented caregiver groups. Results will illuminate the extent to which leveraging prior LBD caregivers as expert interventionists can improve current caregiver outcomes, and in turn, PLBD outcomes. These results will inform future adaptation and dissemination of this model for other conditions.
Recruiting
Has No Placebo
Rush University Medical CenterJori E Fleisher, MD MSCE
Have you considered Rivastigmine clinical trials? We made a collection of clinical trials featuring Rivastigmine, we think they might fit your search criteria.Go to Trials
Image of True Health Center for Functional Medicine in Folsom, United States.

Precision Medicine for Dementia

45 - 76
All Sexes
Folsom, CA
The goal of this clinical trial is to compare a precision medicine approach to the standard-of-care for people with mild cognitive impairment or early-stage dementia. Precision medicine approach starts with the completion of many tests and then the study doctor uses the test results to carefully prepare a treatment plan that is best for the individual person to help treat many of the underlying causes of mild cognitive impairment or early-stage dementia. The main question the study aims to answer is: • Does the precision medicine approach improve memory (cognitive function) better than the current standard-of-care treatment in people with mild cognitive impairment or early-stage dementia during a 9-month treatment period? This is a randomized clinical trial which means that a group of people that meet the study requirements will be assigned at random or by chance (like toss of a coin) to receive either the precision medicine treatment or the current gold standard (standard-of-care). People assigned to the precision medicine group will receive precision medicine for 9-months while those assigned to the standard-of-care group will follow that approach for 9-months, followed by an opportunity to receive up to six months of precision medicine, if desired. Participants will be asked to: * Have their blood drawn for extensive lab testing and collect urine and stool samples as well * Carefully follow instructions received from their study doctor and study team * Make lifestyle changes as prescribed by the study doctor and study team based on your precision medicine program * Take supplements and medications prescribed by the study doctor. * Once officially in the study (after meeting study entry or screening requirements), participate in ten (10) monthly visits with the study doctor, and other members of the study team as scheduled. * Complete cognitive tests at scheduled visits during the study * Have a study partner with you during visits and to help support you on the program Researchers will compare test results between the two study groups to see if the precision medicine approach improves those tests results over the time of the study, resulting in the improvement of cognition over a 9-month treatment period.
Phase 3
Waitlist Available
Quick Reply
True Health Center for Functional Medicine (+6 Sites)Kat Toups, MD
Image of Mayo Clinic Rochester in Rochester, United States.

Caregiver Support Technology for Dementia

18+
All Sexes
Rochester, MN
This research is being done to develop a unique matching process for caregivers of persons living with dementia, such as Alzheimer's disease, Lewy body dementia, frontotemporal degeneration, or other dementia syndromes. Dementia caregivers often assume greater caregiving burden than do non-dementia caregivers, and the caregiving duration tends to be longer. Many caregivers do not have the adequate support they need. Peer-to-peer support has been shown to improve quality of life, more engagement with services, improve caregiver health, and reduce hospitalizations in the person they are caring for. This study will help determine whether caregivers of persons with dementia would find a technology-based caregiver matching program valuable for the purpose of emotional support.
Waitlist Available
Has No Placebo
Mayo Clinic RochesterJulie Fields, PhD, LPMinnesota HealthSolutions
Image of University of Rochester Medical Center for Health + Technology in Rochester, United States.

Palliative Care for Parkinson's Disease

18+
All Sexes
Rochester, NY
The purpose of this study is to learn more about the effectiveness of palliative care training for community physicians and telemedicine support services for patients and carepartners with Parkinson's disease and Lewy Body Dementia (LBD) or related conditions and their care partners. Palliative care is a treatment approach focused on improving quality of life by relieving suffering in the areas of physical symptoms such as pain, psychiatric symptoms such as depression, psychosocial issues and spiritual needs. Telemedicine is the use of technology that allows participants to interact with a health care provider without being physically near the provider.
Recruiting
Quick Reply
Has No Placebo
University of Rochester Medical Center for Health + TechnologyBenzi Kluger, MD
Have you considered Rivastigmine clinical trials? We made a collection of clinical trials featuring Rivastigmine, we think they might fit your search criteria.Go to Trials
Image of Sunnybrook Health Sciences Centre in Toronto, Canada.

Home Sleep Apnea Testing for Cognitive Impairment

Any Age
All Sexes
Toronto, Canada
Obstructive sleep apnea (OSA), which causes abnormal pauses in breathing during sleep, is common in patients with vascular cognitive impairment (VCI) and Alzheimer's disease (AD), and exacerbates the cognitive deficits seen in these conditions. OSA is typically treated with continuous positive airway pressure (CPAP), which has been shown to improve cognition in VCI and slow cognitive decline in AD. Despite the need to identify OSA in patients with VCI/AD, these patients often do not undergo testing for OSA. One major barrier is that in-laboratory polysomnography (iPSG), the current standard for diagnosing OSA, is inconvenient for patients with VCI/AD who may be reliant on others for care or require familiar sleep environments. A convenient and cheaper alternative to iPSG is home sleep apnea testing (HSAT), which has been validated against iPSG to diagnose OSA and has proven feasible for use in VCI/AD. Our primary objective is to determine whether the use of HSAT is superior to iPSG in terms of the proportion of patients who complete sleep testing by 6 months post-randomization. We will also investigate cost-effectiveness, patient satisfaction, proportion of patients treated with CPAP, changes in cognition, mood, sleep-related and functional outcomes between HSAT and iPSG at 6 months.
Recruiting
Has No Placebo
Sunnybrook Health Sciences CentreMark I Boulos, MD, MSc
Image of Vanderbilt University Medical Center in Nashville, United States.

[18F]FDOPA Imaging for Parkinson's Disease

18+
All Sexes
Nashville, TN
Alpha-synucleinopathies refer to age-related neurodegenerative and dementing disorders, characterized by the accumulation of alpha-synuclein in neurons and/or glia. The anatomical location of alpha-synuclein inclusions (Lewy Bodies) and the pattern of progressive neuronal death (e.g. caudal to rostral brainstem) give rise to distinct neurological phenotypes, including Parkinson's disease (PD), Multiple System Atrophy (MSA), Dementia with Lewy Bodies (DLB). Common to these disorders are the involvement of the central and peripheral autonomic nervous system, where Pure Autonomic Failure (PAF) is thought (a) to be restricted to the peripheral autonomic system, and (b) a clinical risk factor for the development of a central synucleinopathy, and (c) an ideal model to assess biomarkers that predict phenoconversion to PD, MSA, or DLB. Such biomarkers would aid in clinical trial inclusion criteria to ensure assessments of disease- modifying strategies to, delay, or halt, the neurodegenerative process. One of these biomarkers may be related to the neurotransmitter dopamine (DA) and related changes in the substantia nigra (SN) and brainstem. \[18F\]F-DOPA is a radiolabeled substrate for aromatic amino acid decarboxylase (AAADC), an enzyme involved in the production of dopamine. Use of this radiolabeled substrate in positron emission tomography (PET) may provide insight to changes in monoamine production and how they relate to specific phenoconversions in PAF patients. Overall, this study aims to identify changes in dopamine production in key regions including the SN, locus coeruleus, and brainstem to distinguish between patients with PD, MSA, and DLB, which may provide vital information to predict conversion from peripheral to central nervous system disease.
Phase 1
Recruiting
Vanderbilt University Medical Center
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security